Cambridge, MA – Sarepta Therapeutics has announced the appointment of Michael Severino as Chief Executive Officer. About Sarepta Therapeutics: Sarepta Therapeutics is a global biotechnology company focused on developing precision genetic medicines for rare diseases that devastate lives and cut futures short. The company describes itself as being on an urgent mission to engineer therapies that can reclaim futures otherwise impacted or cut short by these conditions, and it emphasizes a vision of a revolution in how genetic diseases are treated. Sarepta is actively working to usher in a new era of drug development by shortening the time from lab to patient, building what it positions as the worlds largest gene therapy manufacturing capacity, and rethinking access and reimbursement models for transformative new treatments. Headquartered in Cambridge, Massachusetts, with additional global locations in Ireland, Switzerland, and the United Kingdom, Sarepta operates as an international organization dedicated to serving patients, families, and healthcare providers affected by rare genetic disorders. Overall, the company presents itself as a leader in the rare disease space, combining advanced genetic medicine, large-scale manufacturing ambitions, and innovative approaches to patient access in order to bring groundbreaking therapies to those with serious unmet medical needs.

For more information visit: https://www.sarepta.com/

Sarepta Therapeutics
215 First Street
Cambridge, MA 2142
Phone: 617-274-4000
LinkedIn: https://www.linkedin.com/company/sarepta-therapeutics

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved